Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
0.74-0.01 (-0.74%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.75
Bid0.74 x 1700
Ask0.76 x 1900
Day's Range0.73 - 0.78
52wk Range0.68 - 4.32
1y Target EstN/A
Market Cap42.25M
P/E Ratio (ttm)-1.32
Avg Vol (3m)313,348
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    Ampio Announces Accepted Publication of the Clinical Trial Results of Its Oral Drug, Optina™, Treatment of Diabetic Macular Edema

    ENGLEWOOD, Colo., Oct. 4, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "Potential Beneficial Effect of Low Dose Danazol in Combination With Renin Angiotensin Inhibitors in Diabetic Macular Edema" was accepted for publication in Acta Ophthalmologica, an international peer-reviewed journal in the field of ophthalmology. Ampio's CSO, Dr. David Bar-Or, explained "The article, coauthored by Dr. Michael Singer, retinologist at the University of Texas, reports the clinical benefits of Optina™, from a 12-week multi-center, placebo-controlled, double-masked randomized trial which identified a reversal of pathological changes and a synergistic effect with other medication. Dr. Singer, who previously presented the results of this trial at the World Congress of Ophthalmology and at The Association for Research in Vision and Ophthalmology (ARVO), also presented these findings recently at the 2016 annual meeting of the Retina Society held in San Diego, CA.

  • PR Newswire24 days ago

    Ampio Updates Clinical and Regulatory Activity

    ENGLEWOOD, Colo., Sept. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the Company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe osteoarthritis of the knee (OAK). Michael Macaluso, Ampio's CEO noted, "We are grateful to CBER for their thorough review of our data, which referenced over 1800 patients across multiple trials. CBER's guidance included a number of very good options and as a result, we are continuing discussions.

  • PR Newswirelast month

    Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications

    Dr. David Bar-Or, Ampio's Chief Scientific Officer, explained: "We reported an important positive effect of Ampion™ on stabilization of alpha tubulin (a cytoskeleton protein involved in trafficking molecules inside the cell and important in controlling vascular permeability) in retinal endothelial cells and described the mechanism of action of Ampion™ and a resulting decrease in leakage of fluid through these cells which normally line the interior of blood vessels in the retina.